No hepatitis B reactivation in a patient with refractory antisynthetase syndrome successfully treated with rituximab

Joint Bone Spine

Volumn 78, Issue 6, 2011, Pages 653-654

  Andres, Mariano ^a   Courtney, Philip ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Antisynthetase syndrome; Hepatitis B virus; Lamivudine; Rituximab

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; ENTECAVIR; GLUCOCORTICOID; LAMIVUDINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TENOFOVIR; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ANTISYNTHETASE SYNDROME; CASE REPORT; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JOINT STIFFNESS; LETTER; MALE; MUSCLE BIOPSY; MUSCLE WEAKNESS; NONHUMAN; TREATMENT RESPONSE; VIRUS HEPATITIS; VIRUS REACTIVATION; DRUG EFFECT; MIDDLE AGED; MYOSITIS; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MYOSITIS; RECURRENCE; TREATMENT OUTCOME;

EID: 84855968444     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.05.017     Document Type: Letter

References (8)

1. Sem M., Molberg O., Lund M.B., et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009, 48:968-971.
2. Ríos Fernández R., Callejas Rubio J.L., Sánchez Cano D., et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies: a report of 4 cases and review of the literature. Clin Exp Rheumatol 2009, 27:1009-1016.
3. Imbert-Masseau A., Hamidou M., Agard C., et al. Antisynthetase syndrome. Joint Bone Spine 2003, 70:161-168.
4. Tournadre A., Dubost J.J., Soubrier M. Treatment of inflammatory muscle disease in adults. Joint Bone Spine 2010, 77:390-394.
5. Leung C, Tsoi E, Burns G, et al. An argument for the universal prophylaxis of hepatitis b infection in patients receiving rituximab: A 7-year institutional experience of hepatitis screening. Oncologist 2011. doi:10.1634/theoncologist.2010-0182.
6. Hsu C., Wei S.C., Cheng A.L., et al. Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy [letter]. Hepatology 2009, 50:654-655.
7. Morisco F., Castiglione F., Rispo A., et al. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis 2011, 43:S40-S48.
8. Watanabe M., Shibuya A., Takada J., et al. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med 2010, 21:333-337.